These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2407565)

  • 21. Progesterone alone versus progesterone combined with HCG as luteal support in GnRHa/HMG induced IVF cycles: a randomized clinical trial.
    Mochtar MH; Hogerzeil HV; Mol BW
    Hum Reprod; 1996 Aug; 11(8):1602-5. PubMed ID: 8921100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progesterone levels on the day of human chorionic gonadotropin administration in cycles with gonadotropin-releasing hormone agonist suppression are not predictive of pregnancy outcome.
    Edelstein MC; Seltman HJ; Cox BJ; Robinson SM; Shaw RA; Muasher SJ
    Fertil Steril; 1990 Nov; 54(5):853-7. PubMed ID: 2121554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of early luteal-phase vaginal progesterone supplementation on the outcome of in vitro fertilization and embryo transfer.
    Mui Lam P; Chun Cheung M; Ping Cheung L; Ingrid Lok H; John Haines C
    Gynecol Endocrinol; 2008 Dec; 24(12):674-80. PubMed ID: 19172535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
    Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
    Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration.
    Friedler S; Raziel A; Schachter M; Strassburger D; Bukovsky I; Ron-El R
    Hum Reprod; 1999 Aug; 14(8):1944-8. PubMed ID: 10438404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between flare up and down regulation effects of luteinizing hormone-releasing hormone agonists in an in vitro fertilization program.
    Frydman R; Belaisch-Allart J; Parneix I; Forman R; Hazout A; Testart J
    Fertil Steril; 1988 Sep; 50(3):471-5. PubMed ID: 2970407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol.
    Fatemi HM; Camus M; Kolibianakis EM; Tournaye H; Papanikolaou EG; Donoso P; Devroey P
    Fertil Steril; 2007 Mar; 87(3):504-8. PubMed ID: 17140572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum progesterone levels predict success of in vitro fertilization/embryo transfer in patients stimulated with leuprolide acetate and human menopausal gonadotropins.
    Silverberg KM; Burns WN; Olive DL; Riehl RM; Schenken RS
    J Clin Endocrinol Metab; 1991 Oct; 73(4):797-803. PubMed ID: 1909704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of progesterone on luteinizing hormone release and estradiol/progesterone ratio in the luteal phase of women superovulated for in vitro fertilization and embryo transfer.
    Mahadevan MM; Fleetham J; Taylor PJ
    Fertil Steril; 1988 Dec; 50(6):935-7. PubMed ID: 3203757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Luteal function following ovarian stimulation in rhesus monkeys for in vitro fertilization: atypical response to human chorionic gonadotropin treatment simulating early pregnancy.
    VandeVoort CA; Hess DL; Stouffer RL
    Fertil Steril; 1988 Jun; 49(6):1071-5. PubMed ID: 3131158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study.
    Chakravarty BN; Shirazee HH; Dam P; Goswami SK; Chatterjee R; Ghosh S
    J Steroid Biochem Mol Biol; 2005 Dec; 97(5):416-20. PubMed ID: 16213136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of four protocols for luteal phase support in frozen-thawed Embryo transfer cycles: a randomized clinical trial.
    Zarei A; Sohail P; Parsanezhad ME; Alborzi S; Samsami A; Azizi M
    Arch Gynecol Obstet; 2017 Jan; 295(1):239-246. PubMed ID: 27761732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gonadotropin Releasing Hormone Agonist Final Oocyte Maturation and Human Chorionic Gonadotropin as Exclusive Luteal Support in Normal Responders.
    Beck-Fruchter R; Baram S; Geslevich Y; Weiss A
    Gynecol Obstet Invest; 2019; 84(1):27-34. PubMed ID: 30048969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
    Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program.
    Artini PG; Volpe A; Angioni S; Galassi MC; Battaglia C; Genazzani AR
    J Endocrinol Invest; 1995 Jan; 18(1):51-6. PubMed ID: 7759785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Luteal phase support in in vitro fertilization.
    Yanushpolsky EH
    Semin Reprod Med; 2015 Mar; 33(2):118-27. PubMed ID: 25734349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.